AstraZeneca Aktie
WKN: 886715 / ISIN: US0463531089
| 04.12.2023 14:07:16 | 
Absci, AstraZeneca Join To Deliver AI-designed Antibody Against Oncology Target
(RTTNews) - Absci (ABSI) announced a collaboration with AstraZeneca to deliver an AI-designed antibody against an oncology target. Absci will contribute its generative AI technology to deliver a therapeutic candidate antibody for a specified oncology target. The deal includes an upfront commitment, R&D funding and milestone payments, in addition to royalties on product sales.
Puja Sapra, Senior Vice President of Biologics Engineering & Oncology Targeted Delivery, AstraZeneca said, "This collaboration is an exciting opportunity to utilize Absci's de novo AI antibody creation platform to design a potential new antibody therapy in oncology."
Absci's headquarters is in Vancouver, WA, its AI Research Lab is in New York City, and Innovation Center is in Zug, Switzerland.
Shares of Absci are up 8% in pre-market trade on Monday.
For More Such Health News, visit rttnews.com.
 Der finanzen.at Ratgeber für Aktien!
						
						
						
							
								Der finanzen.at Ratgeber für Aktien!
							
							Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Absci Corporation Registered Shsmehr Nachrichten
| 11.08.25 | Ausblick: Absci mit Zahlen zum abgelaufenen Quartal (finanzen.net) | |
| 12.05.25 | Ausblick: Absci gewährt Anlegern Blick in die Bücher (finanzen.net) | 
Analysen zu Absci Corporation Registered Shsmehr Analysen
Aktien in diesem Artikel
| Absci Corporation Registered Shs | 4,37 | -0,68% |  | 
| AstraZeneca PLC (spons. ADRs) | 70,50 | 0,00% |  | 
 
									 
									 
								